For research use only. Not for therapeutic Use.
Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research[1].
| Catalog Number | I043771 |
| CAS Number | 680188-33-4 |
| Purity | ≥95% |
| Reference | [1]. Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785. |
